Reimagining Medicine Q2 2023 Results
Company overview
Financial review
Conclusions
Appendix
References
INNOVATION
NATALEE results¹ build on Kisqali's differentiated efficacy in mBC,
support expansion into broad population² of stage II, III eBC patients
Ph3 NATALEE trial results 1,2, presented at ASCO 2023
Robust efficacy
Favorable safety
No new safety signals
400mg dose well tolerated, with limited need
for dose reductions
HR
iDFS - total population
0.75
95% CI
(0.62, 0.91)
◉
iDFS - stage II
0.76
(0.53, 1.10)
iDFS - stage III
0.74
(0.59, 0.92)
◉
-
iDFS node negative
0.63
(0.34, 1.16)
iDFS node positive
0.77
(0.63, 0.94)
RFS
0.72
(0.58, 0.88)
◉
DDFS
0.74
(0.60, 0.91)
Low rates of Gr3 symptomatic AEs
OS
0.76
(0.54, 1.07)
-
AE-related discontinuations (<19%) were
mostly protocol-mandated due to lab findings
- most frequent AEs were neutropenia and
liver-related
1. Interim analysis. Slamon D, Stroyakovskiy D, Yardley D, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer. 2. Pending regulatory review and approval.
9 Investor Relations | Q2 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation